Regeneron, Sanofi Skin Cancer Drug Gets Warm Reception from European Regulators
26 April 2019 - 6:48PM
Dow Jones News
By Kimberly Chin
Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SAN.FR)
said a European regulatory panel had issued a positive opinion and
recommended conditional approval for their drug that treats
patients with a common type of skin cancer.
If the drug, Libtayo, wins approval from the European
Commission, it would be the first and only treatment for some
patients with an advanced form of carcinoma in Europe.
Libtayo, which is jointly developed by Regeneron and Paris-based
Sanofi, is a prescription medicine that treats carcinoma patients
with who cannot be cured by surgery or radiation.
The companies said they will need to provide regulators with
additional data from a new group trial to help confirm the benefits
and risk profile of the drug.
European regulators could make a final decision on Libtayo
within the coming months, the companies said.
Shares of Regeneron were down 2.5%, while shares of Sanofi rose
3.5% on Friday.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
April 26, 2019 12:33 ET (16:33 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024